Search Result

Results for "

Ca2 -CaM

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Calmodulin (12) AMPK (2) Apoptosis (2) Autophagy (4) Calcium Channel (2) CaMK (8) Endogenous Metabolite (1) mGluR (2) Phosphodiesterase (PDE) (2)
By Research Areas:	Cancer (3) Cardiovascular Disease (2) Inflammation/Immunology (7) Metabolic Disease (4) Neurological Disease (13)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: CRAC Channel Calmodulin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103319

Calmidazolium chloride R 24571	Autophagy Calmodulin	Neurological Disease Cancer
Calmidazolium chloride (R 24571) is a calmodulin antagonist, antagonizing CaM-dependent phosphodiesterase and calmodulin-induced activation of erythrocyte Ca2+-transporting ATPase with IC₅₀s of 0.15 and 0.35 μM, respectively . Also in anti-cancer research . Calmidazolium binds to calmodulin with a K_d of 3 nM.

HY-P1076A

CALP2 TFA	Calmodulin	Inflammation/Immunology
CALP2 TFA is a calmodulin (CaM) antagonist (K_d of 7.9 µM) with high affinity for binding to the *CaM* EF-hand/Ca ²⁺-binding site. CALP2 TFA inhibits *CaM*-dependent phosphodiesterase activity and increases intracellular Ca ²⁺ concentrations. CALP2 TFA potently inhibits of adhesion and degranulation. CALP2 TFA is also a strong activator of alveolar macrophages .

HY-110140

(E)-KN-93 phosphate	CaMK	Cardiovascular Disease Neurological Disease
(E)-KN-93 phosphate is an inhibitor for Ca ²⁺/calmodulin-dependent protein kinase II (CaMK II) with IC₅₀ of 9 μM and 3 μM, for CaMKIIδ monomer and CaMKIIδ dodecamer. (E)-KN-93 phosphate binds competitively with Ca ²⁺/CaM, and disrupts their interaction with CaMK II, and thus inhibits the CaMK II activation .

HY-19805

STO-609 Maximum Cited Publications 17 Publications Verification	CaMK AMPK Autophagy	Metabolic Disease
STO-609 is a selective and cell-permeable inhibitor of the Ca ²⁺/calmodulin-dependent protein kinase kinase (CaM-KK), with K_i values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC₅₀ ~0.02 g/ml.

HY-P1075

CALP3 2 Publications Verification	Calcium Channel	Neurological Disease Cancer
CALP3, a Ca ²⁺-like peptide, is a potent Ca ²⁺ channel blocker that activates EF hand motifs of Ca ²⁺-binding proteins. CALP3 can functionally mimic increased [Ca ²⁺]_i by modulating the activity of Calmodulin (CaM), Ca ²⁺ channels and pumps. CALP3 has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia .

HY-142087

Beauverolide Ja	Calmodulin Endogenous Metabolite	Neurological Disease
Beauverolide Ja, a cyclotetradepsipeptide, is a potent calmodulin (CaM) inhibitor with a K_d of 0.078 μM and a K_i of 0.39 μM for Ca ²⁺-CaM. Beauverolide Ja is a secondary metabolite of Isaria fumosorosea .

HY-P1076

CALP2	Calmodulin	Inflammation/Immunology
CALP2 is a calmodulin (CaM) antagonist ( (K_d of 7.9 µM)) with high affinity for binding to the *CaM* EF-hand/Ca ²⁺-binding site. CALP2 inhibits *CaM*-dependent phosphodiesterase activity and increases intracellular Ca ²⁺ concentrations. CALP2 potently inhibits of adhesion and degranulation. CALP2 is also a strong activator of alveolar macrophages .

HY-19025

CV-159	Calmodulin	Inflammation/Immunology
CV-159 is a unique dihydropyridine *Ca ²⁺* antagonist with an anti-calmodulin (CaM) action, and has antiinflammatory activities.

HY-P2471

Neurogranin (48-76), mouse	Calmodulin	Neurological Disease
Neurogranin (48-76), mouse is a peptide corresponding to residues 48-76 of Neurogranin. Neurogranin, a calmodulin-binding protein, is exclusively expressed in the post-synapse, and mediates NMDAR driven synaptic plasticity by regulating the calcium-calmodulin (Ca ²⁺-CaM) pathway .

HY-19805A

STO-609 acetate	CaMK AMPK Autophagy	Metabolic Disease
STO-609 acetate is a selective and cell-permeable inhibitor of the Ca ²⁺/calmodulin-dependent protein kinase kinase (CaM-KK), with K_i values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 acetate inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC₅₀ ~0.02 g/ml.

HY-P1077

CALP1	mGluR Phosphodiesterase (PDE) Apoptosis Calmodulin	Inflammation/Immunology
CALP1 is a calmodulin (CaM) agonist (K_d of 88 µM) with binding to the *CaM* EF-hand/Ca ²⁺-binding site. CALP1 blocks calcium influx and apoptosis (IC₅₀ of 44.78 µM) through inhibition of calcium channel opening. CALP1 blocks glutamate receptor channels and blocks a store-operated nonselective cation channel. CALP1 activates *CaM*-dependent phosphodiesterase activity .

HY-P1075A

CALP3 TFA	Calcium Channel	Neurological Disease Cancer
CALP3 TFA, a Ca ²⁺-like peptide, is a potent Ca ²⁺ channel blocker that activates EF hand motifs of Ca ²⁺-binding proteins. CALP3 TFA can functionally mimic increased [Ca ²⁺]_i by modulating the activity of Calmodulin (CaM), Ca ²⁺ channels and pumps. CALP3 TFA has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia .

HY-P1077A

CALP1 TFA 1 Publications Verification	mGluR Phosphodiesterase (PDE) Apoptosis Calmodulin	Inflammation/Immunology
CALP1 TFA is a calmodulin (CaM) agonist (K_d of 88 µM) with binding to the *CaM* EF-hand/Ca ²⁺-binding site. CALP1 TFA blocks calcium influx and apoptosis (IC₅₀ of 44.78 µM) through inhibition of calcium channel opening. CALP1 TFA blocks glutamate receptor channels and blocks a store-operated nonselective cation channel. CALP1 TFA activates *CaM*-dependent phosphodiesterase activity .

HY-P0271

Syntide 2	CaMK Autophagy	Neurological Disease
Syntide 2, a *Ca ²⁺- and calmodulin (CaM)-dependent protein kinase II (CaMKII)* substrate peptide, selectively inhibits the gibberellin (GA) response, leaving constitutive and abscisic acid-regulated events unaffected .

HY-P3944

Calmodulin Dependent Protein Kinase Substrate	CaMK	Neurological Disease
Calmodulin Dependent Protein Kinase Substrate is a *Ca ²⁺- and calmodulin (CaM)-dependent protein kinase* (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate is a synthetic peptide substrate for protein kinases .

HY-P0271A

Syntide 2 TFA 2 Publications Verification	CaMK	Neurological Disease
Syntide 2 (TFA), a *Ca ²⁺- and calmodulin (CaM)-dependent protein kinase II (CaMKII)* substrate peptide, selectively inhibits the gibberellin (GA) response, leaving constitutive and abscisic acid-regulated events unaffected .

HY-P3943

Calmodulin Dependent Protein Kinase Substrate Analog	CaMK	Neurological Disease
Calmodulin Dependent Protein Kinase Substrate Analog is a *Ca ²⁺- and calmodulin (CaM)-dependent protein kinase* (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate Analog is a synthetic peptide substrate for protein kinases .

HY-P10316

CaMKI(299-320) Calmodulin-Dependent Protein Kinase I (299-320) Binding Domain	CaMK	Others
CaMKI (299-320) refers to a peptide consisting of residues 299-320 of Calcium/calmodulin-dependent protein kinase I (CaMKI). CaMKI (299-320), as a protein kinase, has a high affinity interaction with Ca ²⁺-CAM (K_d≤1 nM≤1 nM), which can phosphorylate specific substrate proteins, thereby regulating their activity. CaMKI (299-320) contains the CAM-binding domain and the self-inhibition domain, and CaMKI (299-320) can be used to study cell physiological processes, including cell proliferation, differentiation, and apoptosis .

HY-P1805

Calmodulin Binding Peptide 1	Calmodulin	Neurological Disease
Calmodulin Binding Peptide 1 is a high affinity (pM) CaM-binding peptide derived from smooth muscle myosin light-chain kinase (MLCK peptide), which strongly inhibits IP3-induced Ca ²⁺ release .

HY-115745

Calmodulin antagonist-1	Calmodulin	Cardiovascular Disease
Calmodulin antagonist-1 (A-5) is a calmodulin (CaM) antagonist. Calmodulin antagonist-1 inhibits calmodulin-activated Ca ²⁺-phosphodiesterase (PDE) (IC₅₀=66 μM). Calmodulin antagonist-1 also inhibits trypsin-treated Ca ²⁺-PDE (IC₅₀=560 μM) in a competitive fashion with respect to cyclic GMP .

HY-105118A

Zaldaride maleate CGS-9343B; KW 5617	Calmodulin	Neurological Disease Metabolic Disease Inflammation/Immunology
Zaldaride maleate (CGS-9343B) is a potent, orally active and selective inhibitor of calmodulin. Zaldaride maleate inhibits CaM (calmodulin)-stimulated cAMP phosphodiesterase activity, with an IC₅₀ of 3.3 nM . Zaldaride maleate prevents estrogen-induced transcription activation by ER, reversibly blocks voltage-activated Na ⁺, Ca ²⁺ and K ⁺ currents in PC12 cells and inhibits nAChR .

HY-105118

Zaldaride CGS-9343B free base; KW 5617 free base	Calmodulin	Neurological Disease Metabolic Disease Inflammation/Immunology
Zaldaride (CGS-9343B free base) is a potent, orally active and selective inhibitor of calmodulin. Zaldaride inhibits CaM (calmodulin)-stimulated cAMP phosphodiesterase activity, with an IC₅₀ of 3.3 nM . Zaldaride prevents estrogen-induced transcription activation by ER, reversibly blocks voltage-activated Na ⁺, Ca ²⁺ and K ⁺ currents in PC12 cells and inhibits nAChR .

Cat. No.	Product Name	Target	Research Area

HY-P1076A

CALP2 TFA	Calmodulin	Inflammation/Immunology
CALP2 TFA is a calmodulin (CaM) antagonist (K_d of 7.9 µM) with high affinity for binding to the *CaM* EF-hand/Ca ²⁺-binding site. CALP2 TFA inhibits *CaM*-dependent phosphodiesterase activity and increases intracellular Ca ²⁺ concentrations. CALP2 TFA potently inhibits of adhesion and degranulation. CALP2 TFA is also a strong activator of alveolar macrophages .

HY-P1075

CALP3 2 Publications Verification	Calcium Channel	Neurological Disease Cancer
CALP3, a Ca ²⁺-like peptide, is a potent Ca ²⁺ channel blocker that activates EF hand motifs of Ca ²⁺-binding proteins. CALP3 can functionally mimic increased [Ca ²⁺]_i by modulating the activity of Calmodulin (CaM), Ca ²⁺ channels and pumps. CALP3 has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia .

HY-P1077A

CALP1 TFA 1 Publications Verification	mGluR Phosphodiesterase (PDE) Apoptosis Calmodulin	Inflammation/Immunology
CALP1 TFA is a calmodulin (CaM) agonist (K_d of 88 µM) with binding to the *CaM* EF-hand/Ca ²⁺-binding site. CALP1 TFA blocks calcium influx and apoptosis (IC₅₀ of 44.78 µM) through inhibition of calcium channel opening. CALP1 TFA blocks glutamate receptor channels and blocks a store-operated nonselective cation channel. CALP1 TFA activates *CaM*-dependent phosphodiesterase activity .

HY-P5436

SK-MLCK M13	Peptides	Others
SK-MLCK M13 is a biological active peptide. (M-13 is a peptide that represents CAM-binding domain of Calmodulin (CaM) target proteins. CaM is an ubiquitous Ca2+ binding protein.)

HY-P1076

CALP2	Calmodulin	Inflammation/Immunology
CALP2 is a calmodulin (CaM) antagonist ( (K_d of 7.9 µM)) with high affinity for binding to the *CaM* EF-hand/Ca ²⁺-binding site. CALP2 inhibits *CaM*-dependent phosphodiesterase activity and increases intracellular Ca ²⁺ concentrations. CALP2 potently inhibits of adhesion and degranulation. CALP2 is also a strong activator of alveolar macrophages .

HY-P2471

Neurogranin (48-76), mouse	Calmodulin	Neurological Disease
Neurogranin (48-76), mouse is a peptide corresponding to residues 48-76 of Neurogranin. Neurogranin, a calmodulin-binding protein, is exclusively expressed in the post-synapse, and mediates NMDAR driven synaptic plasticity by regulating the calcium-calmodulin (Ca ²⁺-CaM) pathway .

HY-P1077

CALP1	mGluR Phosphodiesterase (PDE) Apoptosis Calmodulin	Inflammation/Immunology
CALP1 is a calmodulin (CaM) agonist (K_d of 88 µM) with binding to the *CaM* EF-hand/Ca ²⁺-binding site. CALP1 blocks calcium influx and apoptosis (IC₅₀ of 44.78 µM) through inhibition of calcium channel opening. CALP1 blocks glutamate receptor channels and blocks a store-operated nonselective cation channel. CALP1 activates *CaM*-dependent phosphodiesterase activity .

HY-P1075A

CALP3 TFA	Calcium Channel	Neurological Disease Cancer
CALP3 TFA, a Ca ²⁺-like peptide, is a potent Ca ²⁺ channel blocker that activates EF hand motifs of Ca ²⁺-binding proteins. CALP3 TFA can functionally mimic increased [Ca ²⁺]_i by modulating the activity of Calmodulin (CaM), Ca ²⁺ channels and pumps. CALP3 TFA has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia .

HY-P0271

Syntide 2	CaMK Autophagy	Neurological Disease
Syntide 2, a *Ca ²⁺- and calmodulin (CaM)-dependent protein kinase II (CaMKII)* substrate peptide, selectively inhibits the gibberellin (GA) response, leaving constitutive and abscisic acid-regulated events unaffected .

HY-P3944

Calmodulin Dependent Protein Kinase Substrate	CaMK	Neurological Disease
Calmodulin Dependent Protein Kinase Substrate is a *Ca ²⁺- and calmodulin (CaM)-dependent protein kinase* (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate is a synthetic peptide substrate for protein kinases .

HY-P0271A

Syntide 2 TFA 2 Publications Verification	CaMK	Neurological Disease
Syntide 2 (TFA), a *Ca ²⁺- and calmodulin (CaM)-dependent protein kinase II (CaMKII)* substrate peptide, selectively inhibits the gibberellin (GA) response, leaving constitutive and abscisic acid-regulated events unaffected .

HY-P3943

Calmodulin Dependent Protein Kinase Substrate Analog	CaMK	Neurological Disease
Calmodulin Dependent Protein Kinase Substrate Analog is a *Ca ²⁺- and calmodulin (CaM)-dependent protein kinase* (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate Analog is a synthetic peptide substrate for protein kinases .

HY-P10316

CaMKI(299-320) Calmodulin-Dependent Protein Kinase I (299-320) Binding Domain	CaMK	Others
CaMKI (299-320) refers to a peptide consisting of residues 299-320 of Calcium/calmodulin-dependent protein kinase I (CaMKI). CaMKI (299-320), as a protein kinase, has a high affinity interaction with Ca ²⁺-CAM (K_d≤1 nM≤1 nM), which can phosphorylate specific substrate proteins, thereby regulating their activity. CaMKI (299-320) contains the CAM-binding domain and the self-inhibition domain, and CaMKI (299-320) can be used to study cell physiological processes, including cell proliferation, differentiation, and apoptosis .

HY-P1805

Calmodulin Binding Peptide 1	Calmodulin	Neurological Disease
Calmodulin Binding Peptide 1 is a high affinity (pM) CaM-binding peptide derived from smooth muscle myosin light-chain kinase (MLCK peptide), which strongly inhibits IP3-induced Ca ²⁺ release .

Beauverolide Ja	Structural Classification Natural Products Microorganisms Source classification	Calmodulin Endogenous Metabolite
Beauverolide Ja, a cyclotetradepsipeptide, is a potent calmodulin (CaM) inhibitor with a K_d of 0.078 μM and a K_i of 0.39 μM for Ca ²⁺-CaM. Beauverolide Ja is a secondary metabolite of Isaria fumosorosea .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Ca2 -CaM

Inhibitors & Agonists

Peptides

NaturalProducts

Natural
Products